Neurizon Therapeutics LimitedASX: NUZ

Bell Potter Healthcare Conference Presentation

· Issued by Neurizon Therapeutics Limited via ASX

Filed with ASX · · 16 pages · English and French

Summary by 6ix AI

The conference will feature insights from the Chief Executive Officer, Dr. Chris Bremer, and is designed to update investors on the company's growth strategies and upcoming milestones. This filing serves to inform stakeholders about Neurizon's progress and strategic direction in the biotechnology sector.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Bell Potter Healthcare Conference Presentation 19 November 2026 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company...

Neurizon Therapeutics Limited on 6ix

In the deck

Story so far

Earlier from Neurizon Therapeutics

All Neurizon Therapeutics news releases